张斌,陈明,郑博,王新刚,范媛媛,霍勇

• 1:北京大学第一医院心内科心血管病研究所

摘要(Abstract)：

目的评价L-605钴铬合金支架平台、聚丙交酯-乙交酯(PLGA)共聚物载体西罗莫司药物洗脱支架在小型猪冠状动脉过度扩张模型中的安全性和有效性。方法裸金属支架(BMS,15枚)、已上市可降解涂层西罗莫司药物洗脱支架(EXCEL,21枚)和钴铬合金PLGA共聚物载体西罗莫司药物洗脱支架(Co-P-SES,21枚)分组随机置入30头小型猪的前降支(LAD)28枚,回旋支(LCX)13枚,右冠状动脉(RCA)16枚。术后28 d、91 d及182 d复查冠状动脉造影,评价管腔丢失(LL)等指标后处死动物,进行组织形态学及组织病理学分析。结果术后28 d及91 d,各实验组的管腔丢失、新生内膜面积、炎症积分及内皮化积分差异均无统计学意义,但术后28 d Co-P-SES组在扫描电镜下观察内皮化程度优于EXCEL组;术后182 d,Co-P-SES组与EXCEL组在管腔丢失、炎症积分及内皮化积分中差异均无统计学意义,但在内弹力板环绕面积相似的情况下,Co-P-SES组的管腔面积大于EXCEL组[(4.31±0.94)mm2比(2.62±1.17)mm2,P=0.020)],新生内膜面积小于EXCEL组[(1.87±0.53)mm2比(0.84±0.41)mm2,P=0.004)],差异均有统计学意义。结论在小型猪冠状动脉过度扩张模型中,Co-P-SES的安全性与EXCEL类似,在内皮化及减少新生内膜形成方面可能存在一定优势,有必要进一步临床研究以更好地评价其安全性及有效性。

关键词(KeyWords)： 药物洗脱支架;动物实验;生物可降解药物涂层;再狭窄

Abstract:

Keywords:

基金项目(Foundation): 深圳市信立泰生物医疗工程有限公司的部分支持~~

作者(Author): 张斌,陈明,郑博,王新刚,范媛媛,霍勇

参考文献(References)：

• [1]Fattori,R.,Piva,T.Drug-eluting stents in vascular intervention.Lancet,2003,361:247-249.
• [2]Roiron,C.,Sanchez,P.,Bouzamondo,A.,et al.Drug-eluting stents:an uPdated meta-analysis of randomised controlled trials.Heart,2006,92:641-649.
• [3]Park SJ,Kang SJ,Virmani R,et al.In-stent neoatherosclerosis:a fi nal common Pathway of late stent failure.J Am Coll Cardiol,2012,59:2051-2057.
• [4]Silber S,Windecker S,VranckxP,et al.Unrestricted randomised use of two new generation drug-elutingcoronary stents:2-year Patientrelated versus stent-related outcomes from the RESOLUTE All Comers trial.Lancet,2011,377:1241-1247.
• [5]Kereiakes DJ,Cannon LA,Feldman RL,et al.Clinical and angiograPhic outcomes after treatment of de novo coronary stenoses with a novel Platinum chromium thin-strut stent:Primary results of the PERSEUS(ProsPective Evaluation in a Randomized Trial of the Safety and Efficacy of the Use of the TAXUS Element Paclitaxel-Eluting Coronary Stent System)trial.J Am Coll Cardiol,2010,56:264-267.
• [6]Han YL,Zhang L,Yang LX,et al.A new generation of biodegradable Polymer-coated sirolimus-eluting stents for the treatment of coronary artery disease:fi nal 5-year clinical outcomes from the CREATE study.EuroIntervention,2012,22:815-822.
• [7]Mehilli J,Kastrati A,Wessely R,et al.Randomized trial of a nonPolymer-based raPamycin-eluting stent versus a Polymerbased Paclitaxel-eluting stent for the reduction of late lumen loss.Circulation,2006,113:273-279.
• [8]Ormiston JA,SerruysPW,Regar E,et al.A bioabsorbableeverolimuseluting coronary stent system for Patients with single de-novo coronary artery lesions(ABSORB):a ProsPectiveoPen-label trial.Lancet,2008,371:899-907.
• [9]Mehmet Cilingiroglu,Jim Elliott,DevangPatel,et al.Long-term effects of novel biolimus eluting DEVAXAXXESS plus nitinol selfexpanding stent in a porcine coronary model.Catheter Cardiovasc Interv,2006,68:271-279.
• [10]Carter AJ,Aggarwal M,KoPia GA,et al.Long-term effects of polymer-based,slow-release,sirolimus-eluting stents in a porcine coronary model.Cardiovasc Res,2004,63:617-624.
• [11]Schwartz RS,Edelman E,Virmani R,et al.Drug-eluting stents in Preclinical studies:updated consensus recommendations for preclinical evaluation.Circ Cardiovasc Interv,2008,1:143-153.
• [12]Pache J,Kastrati A,Mehilli J,et al.Intracoronary stenting and angiograPhic results:strut thickness effect on restenosis outcome(ISAR-STEREO-2)trial.J Am Coll Cardiol,2003,41:1283-1288.
• [13]Commandeur S,van Beusekom HM,van der Giessen WJ.Polymers,drug release,and drug-eluting stents.J Interv Cardiol,2006,19:500-506.
• [14]Virmani R,Guagliumi G,Farb A.Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent:should we be cautious?Circulation,2004,109:701-705.